The Ledger

AMGN

AMGEN IncHealth Careinsider_universe

Last close $465.67Nov 12, 2026

Day −0.30%

Everything we've seen

?Nov 11, 5:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $468.25 > MA150 $385.35 (+21.5%), MA rising, 3.3% off 52w high, vol 0.43× avg
?Nov 11, 5:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $468.25 > MA150 $385.35 (+21.5%), MA rising, 3.3% off 52w high, vol 0.43× avg
?Nov 5, 2:26 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
AMGN is down 2.34% today with no headline catalyst visible, suggesting this is likely institutional flow or sector rotation rather than a news-driven spike. The move has real conviction behind it given its magnitude. Macro context shows DFF elevated 2.1σ above trend, which pressures rate-sensitive sectors but is less directly relevant to large-cap biotech like AMGN. With 80 minutes remaining, there is enough time for the move to extend into the close if sellers maintain control, but the absence of a clear catalyst and the already-meaningful drawdown from prior close introduce meaningful mean-reversion risk as well. No reversal signals are explicitly present, and no news is available to suggest a catalyst for a snapback. Overall, the base case is mild continuation of selling pressure into the close, but confidence is modest — this is a borderline read with probability just above the 0.5 threshold driven primarily by intraday momentum and adequate time remaining.
!Nov 5, 2:26 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
AMGN is down 2.34% today with no headline catalyst visible, suggesting this is likely institutional flow or sector rotation rather than a news-driven spike. The move has real conviction behind it given its magnitude. Macro context shows DFF elevated 2.1σ above trend, which pressures rate-sensitive sectors but is less directly relevant to large-cap biotech like AMGN. With 80 minutes remaining, there is enough time for the move to extend into the close if sellers maintain control, but the absence of a clear catalyst and the already-meaningful drawdown from prior close introduce meaningful mean-reversion risk as well. No reversal signals are explicitly present, and no news is available to suggest a catalyst for a snapback. Overall, the base case is mild continuation of selling pressure into the close, but confidence is modest — this is a borderline read with probability just above the 0.5 threshold driven primarily by intraday momentum and adequate time remaining.
?Nov 5, 11:46 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
AMGN is down 2.14% with 240 minutes remaining — a meaningful move with ample time to extend. No headlines are available to explain the move, but absence of news is not disqualifying; large institutional flows often precede or operate without public catalysts. The macro context (DFF elevated 2.1σ above trend) signals a higher-rate environment, which is a mild headwind for large-cap biopharma via discount rate pressure on long-duration earnings streams, providing some directional support for the downside thesis. With 4 hours left, there is meaningful time for continuation. However, several factors temper conviction: (1) no news anchor makes it harder to assess whether the selling pressure is exhausted or ongoing; (2) AMGN is a defensive, dividend-paying large-cap that tends to attract buy-the-dip flows intraday; (3) a 2.14% move in a name like AMGN is notable and may have already captured the bulk of the day's repositioning. On balance, there is a slight lean toward continuation given the magnitude of the move and time remaining, but conviction is modest — assigning 0.52 probability of continued downside into the close.
!Nov 5, 11:46 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
AMGN is down 2.14% with 240 minutes remaining — a meaningful move with ample time to extend. No headlines are available to explain the move, but absence of news is not disqualifying; large institutional flows often precede or operate without public catalysts. The macro context (DFF elevated 2.1σ above trend) signals a higher-rate environment, which is a mild headwind for large-cap biopharma via discount rate pressure on long-duration earnings streams, providing some directional support for the downside thesis. With 4 hours left, there is meaningful time for continuation. However, several factors temper conviction: (1) no news anchor makes it harder to assess whether the selling pressure is exhausted or ongoing; (2) AMGN is a defensive, dividend-paying large-cap that tends to attract buy-the-dip flows intraday; (3) a 2.14% move in a name like AMGN is notable and may have already captured the bulk of the day's repositioning. On balance, there is a slight lean toward continuation given the magnitude of the move and time remaining, but conviction is modest — assigning 0.52 probability of continued downside into the close.
?Nov 5, 11:25 AMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $468.58 > MA150 $382.26 (+22.6%), MA rising, 2.9% off 52w high, vol 0.02× avg
!Nov 5, 10:10 AMsignal
Agent 1 — Immutable — insufficient_capital
?Nov 4, 9:41 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
AMGN is up 1.79% intraday, a moderate but meaningful move suggesting real buying interest. No news catalysts are present, but absence of news does not negate the momentum signal. The macro context shows the fed funds rate printing 2.1σ above its 24-month trend, which is modestly negative for equities broadly (tighter financial conditions), but AMGN as a large-cap biotech/pharma name is relatively rate-insensitive compared to banks or growth tech. With 365 minutes remaining (essentially a full trading day ahead given this appears to be a morning read), there is ample time for the move to extend. The 1.79% gain is below the 2-5% 'high conviction' threshold, so this is an ordinary momentum situation rather than a strong continuation setup. No reversal signals are evident from the data provided. Assigning a modest continuation probability above 0.5, reflecting genuine but unremarkable upside momentum with a neutral-to-mildly-headwind macro backdrop.
!Nov 4, 9:41 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
AMGN is up 1.79% intraday, a moderate but meaningful move suggesting real buying interest. No news catalysts are present, but absence of news does not negate the momentum signal. The macro context shows the fed funds rate printing 2.1σ above its 24-month trend, which is modestly negative for equities broadly (tighter financial conditions), but AMGN as a large-cap biotech/pharma name is relatively rate-insensitive compared to banks or growth tech. With 365 minutes remaining (essentially a full trading day ahead given this appears to be a morning read), there is ample time for the move to extend. The 1.79% gain is below the 2-5% 'high conviction' threshold, so this is an ordinary momentum situation rather than a strong continuation setup. No reversal signals are evident from the data provided. Assigning a modest continuation probability above 0.5, reflecting genuine but unremarkable upside momentum with a neutral-to-mildly-headwind macro backdrop.
?Nov 3, 5:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $460.79 > MA150 $380.62 (+21.1%), MA rising, 3.1% off 52w high, vol 0.54× avg
?Nov 3, 5:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $460.79 > MA150 $380.62 (+21.1%), MA rising, 3.1% off 52w high, vol 0.54× avg
?Nov 2, 5:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $465.52 > MA150 $379.89 (+22.5%), MA rising, 2.1% off 52w high, vol 0.90× avg
?Nov 2, 5:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $465.52 > MA150 $379.89 (+22.5%), MA rising, 2.1% off 52w high, vol 0.90× avg
?Oct 29, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $460.73 > MA150 $378.33 (+21.8%), MA rising, 1.6% off 52w high, vol 1.14× avg
?Oct 29, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $460.73 > MA150 $378.33 (+21.8%), MA rising, 1.6% off 52w high, vol 1.14× avg
?Oct 29, 9:50 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
AMGN is up 3.32% intraday with ~355 minutes remaining (early in the session), suggesting meaningful institutional flow drove this move. No headline catalyst is present, but absence of news doesn't disqualify continuation — large moves often reflect pre-positioned flows (e.g., earnings anticipation, analyst action, or sector rotation). The macro context shows a T10Y2Y at 0.29, modestly below trend, which is mildly supportive of defensives like large-cap biotech — AMGN fits that profile as a defensive growth name. With ample time remaining in the session, momentum has room to extend further. The main headwinds are: (1) no clear catalyst to anchor fresh buyers chasing the move, (2) a 3.32% move is already substantial and may attract profit-taking near current levels, (3) the yield curve reading is not strongly supportive. On balance, the setup reflects ordinary momentum with no strong fade signal — probability sits modestly above the 0.5 threshold to favor continuation, consistent with the system's asymmetric risk framework.
!Oct 29, 9:50 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
AMGN is up 3.32% intraday with ~355 minutes remaining (early in the session), suggesting meaningful institutional flow drove this move. No headline catalyst is present, but absence of news doesn't disqualify continuation — large moves often reflect pre-positioned flows (e.g., earnings anticipation, analyst action, or sector rotation). The macro context shows a T10Y2Y at 0.29, modestly below trend, which is mildly supportive of defensives like large-cap biotech — AMGN fits that profile as a defensive growth name. With ample time remaining in the session, momentum has room to extend further. The main headwinds are: (1) no clear catalyst to anchor fresh buyers chasing the move, (2) a 3.32% move is already substantial and may attract profit-taking near current levels, (3) the yield curve reading is not strongly supportive. On balance, the setup reflects ordinary momentum with no strong fade signal — probability sits modestly above the 0.5 threshold to favor continuation, consistent with the system's asymmetric risk framework.
?Oct 27, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $447.95 > MA150 $376.96 (+18.8%), MA rising, 0.7% off 52w high, vol 0.64× avg
?Oct 27, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $447.95 > MA150 $376.96 (+18.8%), MA rising, 0.7% off 52w high, vol 0.64× avg
?Oct 26, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $444.63 > MA150 $376.30 (+18.2%), MA rising, 1.4% off 52w high, vol 0.74× avg
?Oct 26, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $444.63 > MA150 $376.30 (+18.2%), MA rising, 1.4% off 52w high, vol 0.74× avg
?Oct 26, 9:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
AMGN is up 1.60% today with 360 minutes remaining — substantial time left in the session for momentum to continue. The move is real but not extreme (sub-2%), suggesting it could reflect steady institutional accumulation rather than a spike that exhausts itself. No headlines are present, which is neutral per the framework — absence of news does not disqualify the move. The macro context (T10Y2Y at 0.31, 1.6σ below trend) favors defensives in a bear-flattening regime, and AMGN as a large-cap biotech/defensive fits that description reasonably well, providing mild tailwind. However, the yield curve reading is modest and not a strong catalyst. No reversal signals are evident. With ample time, ordinary upward momentum, and a macro environment that is mildly supportive of defensive names, a slight lean toward continuation is warranted — but without volume data or a clear catalyst, confidence is modest.
!Oct 26, 9:45 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
AMGN is up 1.60% today with 360 minutes remaining — substantial time left in the session for momentum to continue. The move is real but not extreme (sub-2%), suggesting it could reflect steady institutional accumulation rather than a spike that exhausts itself. No headlines are present, which is neutral per the framework — absence of news does not disqualify the move. The macro context (T10Y2Y at 0.31, 1.6σ below trend) favors defensives in a bear-flattening regime, and AMGN as a large-cap biotech/defensive fits that description reasonably well, providing mild tailwind. However, the yield curve reading is modest and not a strong catalyst. No reversal signals are evident. With ample time, ordinary upward momentum, and a macro environment that is mildly supportive of defensive names, a slight lean toward continuation is warranted — but without volume data or a clear catalyst, confidence is modest.
?Oct 23, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $439.26 > MA150 $375.67 (+16.9%), MA rising, 2.6% off 52w high, vol 0.46× avg
?Oct 23, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $439.26 > MA150 $375.67 (+16.9%), MA rising, 2.6% off 52w high, vol 0.46× avg
?Oct 22, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $447.28 > MA150 $375.06 (+19.3%), MA rising, 0.8% off 52w high, vol 1.10× avg
?Oct 22, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $447.28 > MA150 $375.06 (+19.3%), MA rising, 0.8% off 52w high, vol 1.10× avg
❖Oct 22, 3:11 PMnewsvia finnhub
Dow Jones Top Movers Today: PG and JNJ Lead Gainers, CAT and AMZN Lead Losers
Dow Jones session movers: PG rose 6.01% and JNJ 4.3% to lead 10 gainers, while CAT fell 5.39%, AMZN 4.98% and NVDA 4.37% to lead 8 losers.
❖Oct 22, 12:41 PMnewsvia finnhub
Dow Jones Top Movers: Gainers and Losers on October 22, 2026
Dow Jones top movers for October 22, 2026: Johnson & Johnson, Salesforce, Home Depot and P&G led gains, while Caterpillar, Nvidia and Amazon led declines.
❖Oct 22, 9:57 AMnewsvia finnhub
BeOne Stock Breaks Out With Visions Of 177% Earnings Growth. This Telltale Clue Bodes Well.
Oncology-focused biotech firm BeOne Medicines pops into buy range, boosted by strong demand and stellar earnings growth.
❖Oct 22, 12:30 AMnewsvia finnhub
AstraZeneca (LSE:AZN) Reports Positive Phase III Results In Eosinophilic Esophagitis
AstraZeneca (LSE:AZN) and Amgen reported positive Phase III results for TEZSPIRE in eosinophilic esophagitis in October 2026. The Phase III trial showed statistically significant and sustained efficacy for TEZSPIRE in patients with eosinophilic esophagitis. These data support a potential label expansion for TEZSPIRE into eosinophilic esophagitis, beyond its currently approved indications. The new Phase III TEZSPIRE success in eosinophilic esophagitis needs weighing against AstraZeneca's...
▣Oct 21, 8:00 PMjournaltarget
Agent 4 — Dip Buyer (Frozen) closed long 2 @ $447.28 (+$139.86)
Target hit: close $447.28 ≥ target $447.03
?Oct 21, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $438.20 > MA150 $374.41 (+17.0%), MA rising, 2.0% off 52w high, vol 0.53× avg
?Oct 21, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $438.20 > MA150 $374.41 (+17.0%), MA rising, 2.0% off 52w high, vol 0.53× avg
❖Oct 21, 5:18 PMnewsvia finnhub
Are You Overpaying For Regeneron Stock Versus Its Rivals?
For questions about this article or underlying research, email help@trefis.com.
❖Oct 21, 1:30 PMnewsvia finnhub
Amgen (AMGN) Sales Grew 10%, but Can Earnings Catch Up to the Price?
Amgen (NASDAQ:AMGN) and AstraZeneca reported Phase 3 results this week for Tezspire in eosinophilic esophagitis, a condition that makes swallowing difficult. The trial met both of its main goals, and the benefit lasted through week 52. Tezspire is approved for severe asthma, so a new use would widen a drug that is already growing fast. […]
❖Oct 21, 1:06 PMnewsvia finnhub
What Changed In Amgen's Story?
For questions about this article or underlying research, email help@trefis.com.
❖Oct 21, 6:43 AMnewsvia finnhub
Amgen and AstraZeneca report Phase III Tezspire data for EoE
The trial evaluated 368 participants aged 12 to 80 years who were permitted to continue stable background therapies.
❖Oct 21, 5:00 AMnewsvia finnhub
Biotech ETF (BBH) Hits New 52-Week High
BBH hits a 52-week high as positive Amgen news and strong momentum fuel gains. Can the biotech ETF rally further?
❖Oct 21, 4:53 AMnewsvia finnhub
Barclays Maintains Equal-Weight on Amgen, Raises Price Target to $400
Barclays analyst Emily Field maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and raises the price target from $380 to $400.
❖Oct 20, 6:05 PMnewsvia finnhub
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.
?Oct 20, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $438.94 > MA150 $373.83 (+17.4%), MA rising, 1.8% off 52w high, vol 0.76× avg
?Oct 20, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $438.94 > MA150 $373.83 (+17.4%), MA rising, 1.8% off 52w high, vol 0.76× avg
❖Oct 20, 5:00 PMnewsvia finnhub
2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)
These drugmakers are facing some near-term challenges, but is that enough to stop their recent momentum?
❖Oct 20, 4:48 PMnewsvia finnhub
Stock Market Today: Dow Jumps On U.S.-Iran Hopes; This Warren Buffett Stock Offers Entry (Live Coverage)
Stock Market Today: The Dow Jones index and other indexes gain Tuesday on U.S.-Iran peace hopes. Biotech and software stocks show strength. A Warren Buffett stock clears an entry.
❖Oct 20, 4:15 PMnewsvia finnhub
AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026
Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress (ESMO) 2026 on Saturday, October 24, 2026 at 11:30 a.m. PT. Murdo Gordon, executive vice president of Global Markets and Policy at Amgen, and Jean-Charles Soria, senior vice president of oncology within Global Development at Amgen, as well as other members of Amgen's management team, will discuss Amgen's oncology portfolio and selected data being present
❖Oct 20, 4:01 PMnewsvia finnhub
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
WILMINGTON, Del., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today announced the appointment of Scott M. Wasserman, MD, to the Company’s Board of Directors, effective October 19, 2026. Concurrent with Dr. Wasserman’s appointment, the Company also announced the resignation of Dennis Berma
❖Oct 20, 3:53 PMnewsvia finnhub
Sector Update: Healthcare Stocks Gain Late Afternoon
Healthcare stocks rose late Tuesday afternoon with the NYSE Healthcare Index gaining 2.2% and the St
❖Oct 20, 3:10 PMnewsvia finnhub
Dow Jones Top Gainers in Today's Session: 3M Leads
Dow Jones top gainers in today's session included 3M, Merck, UnitedHealth, Amgen, Nike, Travelers and Home Depot, with 3M leading the advance at 5.08%.
❖Oct 20, 12:40 PMnewsvia finnhub
Dow Jones Top Gainers on Oct. 20, 2026: MMM, UNH, MRK Lead Session
Dow Jones top gainers for the Oct. 20, 2026 US session included MMM, UNH, MRK, JNJ, and AMGN, with the article noting their gains and longer-term performance.
✓Oct 20, 9:56 AMdecisionacted
Agent 7 — Day Trader — decide: buy
AMGN is up 2.39% today following a headline indicating an earnings beat has positively shifted its investment narrative. This is meaningful fundamental-driven flow — earnings beats in biotech/large-cap pharma tend to sustain momentum through the session as institutional buyers average in and analysts update estimates. With 350 minutes remaining (essentially the full remaining session), there is ample time for continuation. The macro context (elevated 2Y rates at 2σ above trend) is a modest headwind for long-duration growth assets, but AMGN is a large-cap defensive-leaning biotech with strong cash flows, making it less sensitive to rate pressure than pure growth names. No reversal signals or fade patterns are noted. The absence of a competing negative catalyst and the presence of a clear positive earnings-driven catalyst support continuation. Probability set at 0.62 — solid momentum with a credible catalyst, slightly tempered by the elevated rate environment and the fact that the move, while meaningful, is not accompanied by explicit volume confirmation data.
❖Oct 20, 8:51 AMnewsvia finnhub
AstraZeneca/Amgen Drug Shows Significant Remission in Eosinophilic Esophagitis Study
AstraZeneca and Amgen report positive Phase 3 Tezspire data, showing sustained remission in eosinophilic esophagitis patients over 52 weeks.
❖Oct 20, 7:02 AMnewsvia finnhub
Is Eli Lilly Stock Too Dependent On Two Drugs?
Two drugs, Mounjaro and Zepbound, accounted for $14.9 billion of Eli Lilly's (LLY) $23.0 billion in revenue during fiscal Q2 2026. This leaves Eli Lilly relying on two medicines for most of its sales at a time when the price it gets for them is falling. So why is so much of Eli Lilly's business running through two drugs.
❖Oct 20, 5:06 AMnewsvia finnhub
Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points
Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the positive Phase 3 CROSSING trial that showed TEZSPIRE® (tezepelumab-ekko) demonstrated statistically significant and clinically meaningful
❖Oct 20, 5:06 AMnewsvia finnhub
AstraZeneca And Amgen's TEZSPIRE Met Co-Primary Endpoints In Phase III EoE Trial
First and only biologic therapy to achieve statistically significant and clinically meaningful histologic remission and symptom improvements at week 24 that were sustained through week 52 vs. placeboTEZSPIRE attained
❖Oct 19, 11:23 PMnewsvia finnhub
How Earnings Beat At Amgen Stock Has Changed Its Investment Story
Amgen recently reported a 10% rise in second quarter revenue, continued to beat earnings and sales estimates, and maintained a dividend yield of 2.5% with annual increases of 8% from 2020 to 2025. The combination of consistent estimate beats, modest upward earnings revisions and faster dividend growth than Merck signals a business leaning on disciplined capital returns as well as expanding newer therapies. We will look at how Amgen's investment narrative is influenced by sustained dividend...
❖Oct 19, 9:04 PMnewsvia finnhub
15 Undervalued Stocks: Yield Up To 7.8% And 15 Overvalued Not To Pursue Now
RIG portfolio review ranks 15 undervalued vs. 15 overvalued dividend stocks using 52-week highs/lows. Check out the list here.
▢Oct 19, 8:00 PMjournal
Agent 7 — Day Trader opened long 6 @ $435.10
▣Oct 19, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 6 @ $437.07 (+$11.82)
EOD forced close — day trader never carries overnight
?Oct 19, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $424.94 > MA150 $373.31 (+13.8%), MA rising, 4.9% off 52w high, vol 0.92× avg
❖Oct 19, 5:39 PMnewsvia finnhub
Merck vs. Amgen: Which Dividend Stock Pays You More in 10 Years?
Key TakeawaysMerck raised its 2026 sales outlook on Aug. 4, the same day Amgen reported second-quarter revenue up 10%.
❖Oct 19, 4:40 PMnewsvia finnhub
Stock Market Today: Dow Dips As Oil Jumps, Nasdaq Pops; Amazon Stock Rallies On This
The Dow Jones index slips even as tech stocks climb on stock market today. Amazon and Nvidia rebound while a biotech stock tests a buy point.
❖Oct 19, 1:16 PMnewsvia finnhub
How Much Upside Is Left In Regeneron Stock?
Regeneron Pharmaceuticals (REGN) stock returned 37.9% in the year to October 16, 2026. This easily outpaced the 16.2% gain for the S&P 500 and left investors looking at a higher price. The underlying business has grown faster lately, yet its operating margin has slipped in each of the past three years. If you buy or hold the shares today, what could three more years of owning them make you.
❖Oct 19, 12:16 PMnewsvia finnhub
Mattel names second CFO in under 18 months
Peter Griffith joins from a biotech company. Paul Ruh, who has been CFO since the spring of 2025, will serve as an adviser through the end of the year.
❖Oct 19, 10:07 AMnewsvia finnhub
Amgen Has the Drugs and the Dividend. Now It Needs the Growth
Amgen Inc. (NASDAQ:AMGN) has carved out a strong spot in the biotech world, thanks to its lineup of medicines for cancer, heart disease, inflammation, and some rare conditions. The company’s tried-and-true products bring in plenty of cash, and its newer treatments show real promise for growth. For those looking beyond a single pharmaceutical stock, the 10 […]
❖Oct 19, 8:00 AMnewsvia finnhub
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
❖Oct 18, 7:27 PMnewsvia finnhub
The Winners Inside SCHD - October 2026
❖Oct 17, 12:46 AMnewsvia finnhub
Amgen's Q3 2026 Earnings: What to Expect
Amgen is scheduled to report its third-quarter results next month, and analysts expect a single-digit earnings rise.
❖Oct 16, 10:57 PMnewsvia finnhub
What Was Eli Lilly Telling You Before Its Stock Ran?
An investor who put $10,000 into Eli Lilly (LLY) stock on October 14, 2025 held about $15,500 by October 15, 2026. Placing that same sum in the S&P 500 over the identical period would have yielded about $11,790. By mid-2026, two drugs, Zepbound and Mounjaro, accounted for most of the company's sales. How early did those two drugs show up in what Lilly said and filed.
❖Oct 16, 8:53 PMnewsvia finnhub
When Amgen's Forecast And Chart Say The Same Thing, Pay Attention
Amgen (AMGN) raised its revenue forecast for fiscal 2026 on August 4. Since the market close before that release, the stock has gained 15.2%, outpacing the 1.9% return of the S&P 500. A higher forecast or a climbing share price means little in isolation. When the corporate numbers and the technical chart align, however, the combination warrants closer scrutiny. So how far did management raise its forecast, and why.
❖Oct 16, 8:13 PMnewsvia finnhub
Is Amgen Stock Increasing Your Market Risk?
Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair that position with broad exposure to the S&P 500. As the broader market rises and falls each day, the pharmaceutical stock's individual performance blends with the rest of that capital. So when the market drops, does Amgen make your losses bigger.
?Oct 16, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $432.56 > MA150 $372.92 (+16.0%), MA rising, 3.2% off 52w high, vol 0.50× avg
❖Oct 16, 4:49 PMnewsvia finnhub
Moderna Stock Slumps, but It’s Too Early to Panic
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.
❖Oct 16, 3:43 PMnewsvia finnhub
9 Dow Jones Stocks Make Bullish Moves In A Defensive Market Rotation
A week that tested the financial markets showed the resilience of Dow Jones stocks. Apple and Coca-Cola were among nine standouts.
❖Oct 16, 3:36 PMnewsvia finnhub
Moderna and Novavax Stocks Slump as Biotech’s Rally Takes a Breather
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat.
❖Oct 16, 7:30 AMnewsvia finnhub
Here's How Much $100 Invested In Amgen 15 Years Ago Would Be Worth Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 1.45% on an annualized basis producing an average annual return of 14.3%. Currently, Amgen has a market capitalization of $230.37 billion.
❖Oct 16, 4:28 AMnewsvia finnhub
Biogen: The Bull Case Is Extending Beyond Alzheimer's (Rating Upgrade)
Biogen's Q3 earnings are due Oct 28. Explore FY2026 EPS guidance, Alzheimerâs revenue growth, and key risk/reward driversâread now. Click for this BIIB update.
?Oct 15, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $434.03 > MA150 $372.48 (+16.5%), MA rising, 2.9% off 52w high, vol 0.90× avg
❖Oct 15, 4:50 PMnewsvia finnhub
Amgen (AMGN) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Amgen (AMGN) settling at $434.03, representing a +1.86% change from its previous close.
❖Oct 15, 3:10 PMnewsvia finnhub
Discover which dow jones stocks are making waves on Thursday.
Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.
✓Oct 15, 1:41 PMdecisionacted
Agent 7 — Day Trader — decide: buy
AMGN is up 3.35% today, a meaningful move indicating real institutional flow. With 125 minutes remaining there is adequate time for continuation into the close. The macro context (elevated mortgage rates at 7.4%) is not directly relevant to a large-cap biotech/pharma name like Amgen, so it neither supports nor undermines the move. The sole headline is generic Dow Jones session commentary, offering no contrary signal or reversal catalyst. Absence of a specific news driver is not a disqualifier per the framework. The move itself is the signal — a 3%+ gap or intraday surge in a Dow component typically reflects real accumulation (earnings estimate revision, pipeline news, or sector rotation into defensives/healthcare). No reversal pattern is described, no volume warning flags are present. The setup is ordinary positive momentum with no strong reason to fade, placing this in the 0.5-0.65 band. Assigning 0.55 reflecting moderate conviction: the move has merit and time to run, but without clearer catalysts or volume confirmation, high-confidence continuation cannot be claimed.
❖Oct 15, 12:45 PMnewsvia finnhub
AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow
Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cushion that changes the entire income calculus.
❖Oct 15, 12:40 PMnewsvia finnhub
These dow jones stocks are moving in today's session
Stay updated with the movements of the dow jones index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session.
▢Oct 14, 8:00 PMjournal
Agent 7 — Day Trader opened long 6 @ $440.39
▣Oct 14, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 6 @ $438.07 (-$13.95)
EOD forced close — day trader never carries overnight
❖Oct 14, 5:45 PMnewsvia finnhub
What Could Send Regeneron Stock Higher?
Regeneron Pharmaceuticals (REGN) may get its next boost from an old deal rather than a new drug. Through the first half of 2026, Regeneron was paying down a balance owed to its partner Sanofi. This obligation reduced the revenue Regeneron reported from the partnership. So what does Regeneron gain now that the balance is paid off.
❖Oct 14, 3:10 PMnewsvia finnhub
Discover which dow jones stocks are making waves on Wednesday.
Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Wednesday.
❖Oct 14, 12:40 PMnewsvia finnhub
These dow jones stocks are moving in today's session
Curious about the top performers within the dow jones index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
❖Oct 14, 12:35 PMnewsvia finnhub
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.
❖Oct 14, 11:25 AMnewsvia finnhub
Amgen (AMGN) Gains Attention On Aging Treatments, Is The Upside Already Priced In?
Why Amgen Stock Is Back In Focus Amgen (AMGN) moved into the spotlight after its share price climbed sharply alongside growing attention on treatments for age related conditions in the U.S., putting its role in an aging society under closer investor scrutiny. Over the past few months, momentum around Amgen has picked up, with a 30 day share price return of 9.41% and a 90 day move of 15.22% helping lift the stock to US$412.84. The 1 year total shareholder return of 44.39% and 5 year total...
?Oct 14, 10:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
AMGN is up ~3% today with no single clear catalyst visible in headlines — the move appears driven by internal flow or sector rotation into defensive pharma/biotech names. Headlines are generically supportive of healthcare/pharma as a sector (aging population, dividend pharma), consistent with the move but not a strong individual catalyst. The macro context shows 5Y5Y inflation forwards elevated at 1.5σ above trend, which is mildly headwind for rate-sensitive equities broadly, but large-cap defensive biotech like AMGN tends to hold up reasonably well in that environment given its dividend and cash flow profile. With 300 minutes remaining (effectively a full afternoon session), there is ample time for continuation if buyers remain engaged. The 3% move is meaningful and suggests real institutional flow. No reversal signals are apparent from the data provided. However, the absence of a specific catalyst (FDA approval, earnings beat, etc.) and the slightly elevated inflation forward rate create some fade risk as the afternoon progresses. Overall, a modest continuation bias is warranted — the move is real and time remains, but conviction is moderate without a clear identifiable driver.
!Oct 14, 10:45 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
AMGN is up ~3% today with no single clear catalyst visible in headlines — the move appears driven by internal flow or sector rotation into defensive pharma/biotech names. Headlines are generically supportive of healthcare/pharma as a sector (aging population, dividend pharma), consistent with the move but not a strong individual catalyst. The macro context shows 5Y5Y inflation forwards elevated at 1.5σ above trend, which is mildly headwind for rate-sensitive equities broadly, but large-cap defensive biotech like AMGN tends to hold up reasonably well in that environment given its dividend and cash flow profile. With 300 minutes remaining (effectively a full afternoon session), there is ample time for continuation if buyers remain engaged. The 3% move is meaningful and suggests real institutional flow. No reversal signals are apparent from the data provided. However, the absence of a specific catalyst (FDA approval, earnings beat, etc.) and the slightly elevated inflation forward rate create some fade risk as the afternoon progresses. Overall, a modest continuation bias is warranted — the move is real and time remains, but conviction is moderate without a clear identifiable driver.
❖Oct 14, 10:14 AMnewsvia finnhub
What Could Amgen (AMGN) 70% Remission Trial Result Mean For Its Pipeline?
Amgen (NasdaqGS:AMGN) and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis on 14 October 2026. In the trial, nearly 70% of patients receiving the higher Tezspire dose achieved remission at week 24. The study targeted eosinophilic esophagitis, a chronic inflammatory condition that currently has limited approved treatment options. The Tezspire eosinophilic esophagitis Phase 3 success is only one part of the wider Amgen story investors may want to...
?Oct 9, 3:30 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
AMGN is up 2.12% today with no clear catalyst visible in recent headlines — the move may reflect broader sector rotation or institutional flow, but with only 15 minutes remaining until the forced close, there is virtually no runway for continuation to reach the +3% profit target. At current price of $416.08, a +3% target would require reaching ~$428.57 in 15 minutes, which is highly unlikely absent a major catalyst. The macro backdrop (mortgage rates at 7.4%, 3.8σ above trend) is not directly relevant to biotech/pharma. The Alumis psoriasis headline is competitor news and lukewarm per analysts, providing no positive read-through. With time this short, even genuine momentum setups fade in probability simply due to insufficient time for the trade to work. The risk/reward does not favor entry here.
!Oct 9, 3:30 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
AMGN is up 2.12% today with no clear catalyst visible in recent headlines — the move may reflect broader sector rotation or institutional flow, but with only 15 minutes remaining until the forced close, there is virtually no runway for continuation to reach the +3% profit target. At current price of $416.08, a +3% target would require reaching ~$428.57 in 15 minutes, which is highly unlikely absent a major catalyst. The macro backdrop (mortgage rates at 7.4%, 3.8σ above trend) is not directly relevant to biotech/pharma. The Alumis psoriasis headline is competitor news and lukewarm per analysts, providing no positive read-through. With time this short, even genuine momentum setups fade in probability simply due to insufficient time for the trade to work. The risk/reward does not favor entry here.
?Oct 8, 1:25 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
AMGN is down 1.73% today, a meaningful but not outsized move. The argenx Sjogren's setback headline could create some sector-level biotech/biopharma anxiety that pressures AMGN sympathetically, though AMGN is not directly exposed. The 'What Would It Take For Amgen Stock To Move Higher?' article suggests a cautious fundamental backdrop. Macro context (mortgage rates 3.8σ above trend) is not directly relevant to AMGN. With 140 minutes remaining there is meaningful time for continuation, but the move is modest and lacks a strong identifiable catalyst to drive further selling conviction. No clear reversal signal is present, so default lean is mild continuation. Probability set just above 0.5 reflecting ordinary momentum with no strong counter-thesis, but lacking the volume confirmation or sector catalyst needed for higher conviction.
!Oct 8, 1:25 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
AMGN is down 1.73% today, a meaningful but not outsized move. The argenx Sjogren's setback headline could create some sector-level biotech/biopharma anxiety that pressures AMGN sympathetically, though AMGN is not directly exposed. The 'What Would It Take For Amgen Stock To Move Higher?' article suggests a cautious fundamental backdrop. Macro context (mortgage rates 3.8σ above trend) is not directly relevant to AMGN. With 140 minutes remaining there is meaningful time for continuation, but the move is modest and lacks a strong identifiable catalyst to drive further selling conviction. No clear reversal signal is present, so default lean is mild continuation. Probability set just above 0.5 reflecting ordinary momentum with no strong counter-thesis, but lacking the volume confirmation or sector catalyst needed for higher conviction.
?Oct 8, 10:35 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
AMGN is down 2.67% today with ~310 minutes remaining — substantial time for continuation. The argenx biotech selloff (Sjogren's trial failure) likely triggered sector-wide biotech/biopharma risk-off sentiment, pulling AMGN lower alongside peers even without a company-specific catalyst. The headline 'What Would It Take For Amgen Stock To Move Higher?' suggests a cautious analyst narrative backdrop. Macro context shows 5-year forward inflation expectations elevated at 1.8σ above trend, which is modestly negative for high-multiple rate-sensitive names like large-cap biotech. A -2.67% move represents real institutional flow and conviction. However, there is no direct AMGN-specific negative catalyst visible (the argenx news is indirect sector contagion), which limits strong conviction in further continuation. With ample time remaining and sector pressure still active mid-session, the balance tips modestly toward continuation rather than mean reversion, but this is a borderline read.
!Oct 8, 10:35 AMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
AMGN is down 2.67% today with ~310 minutes remaining — substantial time for continuation. The argenx biotech selloff (Sjogren's trial failure) likely triggered sector-wide biotech/biopharma risk-off sentiment, pulling AMGN lower alongside peers even without a company-specific catalyst. The headline 'What Would It Take For Amgen Stock To Move Higher?' suggests a cautious analyst narrative backdrop. Macro context shows 5-year forward inflation expectations elevated at 1.8σ above trend, which is modestly negative for high-multiple rate-sensitive names like large-cap biotech. A -2.67% move represents real institutional flow and conviction. However, there is no direct AMGN-specific negative catalyst visible (the argenx news is indirect sector contagion), which limits strong conviction in further continuation. With ample time remaining and sector pressure still active mid-session, the balance tips modestly toward continuation rather than mean reversion, but this is a borderline read.
?Oct 7, 11:15 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
AMGN is up 2.78% intraday, a meaningful move, but several factors weigh against continuation. The most significant headwind is the Morgan Stanley downgrade this morning — maintaining Equal-Weight while cutting the price target to $359, well below the current price of $413.79. That analyst action creates a ceiling narrative and suggests institutional sellers may use today's strength to distribute. The $30M Series A AI genetic testing investment is a minor positive but insufficient to explain or sustain a move of this magnitude. The macro context shows the 5Y5Y forward inflation rate at 1.8σ above trend, which is a headwind for rate-sensitive sectors broadly; large-cap biopharma with bond-proxy characteristics like AMGN can face pressure in elevated real rate environments. With 270 minutes remaining there is ample time for fade, particularly given that the morning catalyst (the MS price target cut) creates overhead resistance as momentum traders who bought the dip realize the analyst community is not supportive. The combination of a bearish analyst action with a price target materially below current trading, elevated rate backdrop, and a move that may already have absorbed initial buying flow tips the probability just below the 0.5 threshold.
!Oct 7, 11:15 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
AMGN is up 2.78% intraday, a meaningful move, but several factors weigh against continuation. The most significant headwind is the Morgan Stanley downgrade this morning — maintaining Equal-Weight while cutting the price target to $359, well below the current price of $413.79. That analyst action creates a ceiling narrative and suggests institutional sellers may use today's strength to distribute. The $30M Series A AI genetic testing investment is a minor positive but insufficient to explain or sustain a move of this magnitude. The macro context shows the 5Y5Y forward inflation rate at 1.8σ above trend, which is a headwind for rate-sensitive sectors broadly; large-cap biopharma with bond-proxy characteristics like AMGN can face pressure in elevated real rate environments. With 270 minutes remaining there is ample time for fade, particularly given that the morning catalyst (the MS price target cut) creates overhead resistance as momentum traders who bought the dip realize the analyst community is not supportive. The combination of a bearish analyst action with a price target materially below current trading, elevated rate backdrop, and a move that may already have absorbed initial buying flow tips the probability just below the 0.5 threshold.
?Oct 6, 3:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] AMGN is an established large-cap biopharma with no evidence of fundamental deterioration in recent filings and no guidance cuts or going-concern language flagged. The options flow is notably bullish — call volume is elevated relative to puts (P/C ratio 0.24, call z-score = -3.92 in absolute volume terms but the skew strongly favors calls), which is a positive informed-money signal on a dipping stock. The 11.1% pullback appears sector-driven rather than idiosyncratic, as Health Care (XLV) is underperforming SPY over both 5- and 30-day windows, supporting mean-reversion candidacy. Offsetting factors include earnings in 27 days (a meaningful headwind, -1 signal), elevated 10Y yield at 5.28% (a headwind for duration-sensitive names), and no insider buying to reinforce conviction.
?Oct 6, 3:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] AMGN is down 11.1% from its 30-day high, a moderate dip with no confirmed fundamental impairment — no guidance cut, no negative SEC filing metrics disclosed, and no bearish news headlines explaining the decline. The options flow is notably bullish: call volume is highly elevated (z=-3.92 in absolute terms but the P/C ratio of 0.24 signals heavy call-side interest relative to puts), which is a meaningful confirmation signal of informed buying on the dip. Earnings are 27 days away, which warrants elevated caution but is not a hard veto; at ~$397 vs. a consensus EPS of $5.91 for the upcoming quarter, AMGN trades at a historically reasonable forward multiple for a large-cap biotech with durable cash flows and a robust pipeline. The sector (XLV) has underperformed SPY over 30 days (-5.34pts), suggesting the dip is partly sector-driven rather than purely idiosyncratic, which supports mean-reversion potential as the sector stabilizes.
?Oct 6, 2:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] AMGN is an established large-cap biopharma with no evidence of fundamental deterioration in recent filings and no guidance cuts or going-concern language flagged. The options flow is notably bullish — call volume is elevated relative to puts (P/C ratio 0.24, call z-score = -3.92 in absolute volume terms but the skew strongly favors calls), which is a positive informed-money signal on a dipping stock. The 11.1% pullback appears sector-driven rather than idiosyncratic, as Health Care (XLV) is underperforming SPY over both 5- and 30-day windows, supporting mean-reversion candidacy. Offsetting factors include earnings in 27 days (a meaningful headwind, -1 signal), elevated 10Y yield at 5.28% (a headwind for duration-sensitive names), and no insider buying to reinforce conviction.
?Oct 6, 2:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] AMGN is down 11.1% from its 30-day high, a moderate dip with no confirmed fundamental impairment — no guidance cut, no negative SEC filing metrics disclosed, and no bearish news headlines explaining the decline. The options flow is notably bullish: call volume is highly elevated (z=-3.92 in absolute terms but the P/C ratio of 0.24 signals heavy call-side interest relative to puts), which is a meaningful confirmation signal of informed buying on the dip. Earnings are 27 days away, which warrants elevated caution but is not a hard veto; at ~$397 vs. a consensus EPS of $5.91 for the upcoming quarter, AMGN trades at a historically reasonable forward multiple for a large-cap biotech with durable cash flows and a robust pipeline. The sector (XLV) has underperformed SPY over 30 days (-5.34pts), suggesting the dip is partly sector-driven rather than purely idiosyncratic, which supports mean-reversion potential as the sector stabilizes.
?Oct 6, 1:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] AMGN is down 11.1% from its 30-day high, a moderate dip with no confirmed fundamental impairment — no guidance cut, no negative SEC filing metrics disclosed, and no bearish news headlines explaining the decline. The options flow is notably bullish: call volume is highly elevated (z=-3.92 in absolute terms but the P/C ratio of 0.24 signals heavy call-side interest relative to puts), which is a meaningful confirmation signal of informed buying on the dip. Earnings are 27 days away, which warrants elevated caution but is not a hard veto; at ~$397 vs. a consensus EPS of $5.91 for the upcoming quarter, AMGN trades at a historically reasonable forward multiple for a large-cap biotech with durable cash flows and a robust pipeline. The sector (XLV) has underperformed SPY over 30 days (-5.34pts), suggesting the dip is partly sector-driven rather than purely idiosyncratic, which supports mean-reversion potential as the sector stabilizes.
?Oct 6, 1:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] AMGN is an established large-cap biopharma with no evidence of fundamental deterioration in recent filings and no guidance cuts or going-concern language flagged. The options flow is notably bullish — call volume is elevated relative to puts (P/C ratio 0.24, call z-score = -3.92 in absolute volume terms but the skew strongly favors calls), which is a positive informed-money signal on a dipping stock. The 11.1% pullback appears sector-driven rather than idiosyncratic, as Health Care (XLV) is underperforming SPY over both 5- and 30-day windows, supporting mean-reversion candidacy. Offsetting factors include earnings in 27 days (a meaningful headwind, -1 signal), elevated 10Y yield at 5.28% (a headwind for duration-sensitive names), and no insider buying to reinforce conviction.
?Oct 6, 12:21 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] AMGN is down 11.1% from its 30-day high, a moderate dip with no confirmed fundamental impairment — no guidance cut, no negative SEC filing metrics disclosed, and no bearish news headlines explaining the decline. The options flow is notably bullish: call volume is highly elevated (z=-3.92 in absolute terms but the P/C ratio of 0.24 signals heavy call-side interest relative to puts), which is a meaningful confirmation signal of informed buying on the dip. Earnings are 27 days away, which warrants elevated caution but is not a hard veto; at ~$397 vs. a consensus EPS of $5.91 for the upcoming quarter, AMGN trades at a historically reasonable forward multiple for a large-cap biotech with durable cash flows and a robust pipeline. The sector (XLV) has underperformed SPY over 30 days (-5.34pts), suggesting the dip is partly sector-driven rather than purely idiosyncratic, which supports mean-reversion potential as the sector stabilizes.
?Oct 6, 12:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] [not executed — reserve_floor_or_cash] AMGN is an established large-cap biopharma with no evidence of fundamental deterioration in recent filings and no guidance cuts or going-concern language flagged. The options flow is notably bullish — call volume is elevated relative to puts (P/C ratio 0.24, call z-score = -3.92 in absolute volume terms but the skew strongly favors calls), which is a positive informed-money signal on a dipping stock. The 11.1% pullback appears sector-driven rather than idiosyncratic, as Health Care (XLV) is underperforming SPY over both 5- and 30-day windows, supporting mean-reversion candidacy. Offsetting factors include earnings in 27 days (a meaningful headwind, -1 signal), elevated 10Y yield at 5.28% (a headwind for duration-sensitive names), and no insider buying to reinforce conviction.
?Oct 6, 10:20 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
[not executed — reserve_floor_or_cash] AMGN is down 11.1% from its 30-day high, a moderate dip with no confirmed fundamental impairment — no guidance cut, no negative SEC filing metrics disclosed, and no bearish news headlines explaining the decline. The options flow is notably bullish: call volume is highly elevated (z=-3.92 in absolute terms but the P/C ratio of 0.24 signals heavy call-side interest relative to puts), which is a meaningful confirmation signal of informed buying on the dip. Earnings are 27 days away, which warrants elevated caution but is not a hard veto; at ~$397 vs. a consensus EPS of $5.91 for the upcoming quarter, AMGN trades at a historically reasonable forward multiple for a large-cap biotech with durable cash flows and a robust pipeline. The sector (XLV) has underperformed SPY over 30 days (-5.34pts), suggesting the dip is partly sector-driven rather than purely idiosyncratic, which supports mean-reversion potential as the sector stabilizes.
?Oct 6, 10:20 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: buy
[not executed — reserve_floor_or_cash] AMGN is an established large-cap biopharma with no evidence of fundamental deterioration in recent filings and no guidance cuts or going-concern language flagged. The options flow is notably bullish — call volume is elevated relative to puts (P/C ratio 0.24, call z-score = -3.92 in absolute volume terms but the skew strongly favors calls), which is a positive informed-money signal on a dipping stock. The 11.1% pullback appears sector-driven rather than idiosyncratic, as Health Care (XLV) is underperforming SPY over both 5- and 30-day windows, supporting mean-reversion candidacy. Offsetting factors include earnings in 27 days (a meaningful headwind, -1 signal), elevated 10Y yield at 5.28% (a headwind for duration-sensitive names), and no insider buying to reinforce conviction.
?Oct 5, 12:20 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is a fundamentally sound large-cap biotech with no confirmed negative catalyst driving the 10.5% drop from the 30-day high. However, the options flow is a significant concern — highly unusual put volume (P/C ratio of 2.81, call z-score of -3.85) on the most recent trading day suggests informed hedging or directional bearish positioning, not a bullish overreaction setup. Earnings are 28 days away (elevated caution zone), sector health care is underperforming SPY on both 5d and 30d bases, and the 10Y yield at 5.24% is a structural headwind for a dividend-paying biotech. No insider buying, no unusual call flow, and no analyst upgrade signals are present to provide confirmation of a rebound.
!Oct 5, 12:20 PMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is a fundamentally sound large-cap biotech with no confirmed negative catalyst driving the 10.5% drop from the 30-day high. However, the options flow is a significant concern — highly unusual put volume (P/C ratio of 2.81, call z-score of -3.85) on the most recent trading day suggests informed hedging or directional bearish positioning, not a bullish overreaction setup. Earnings are 28 days away (elevated caution zone), sector health care is underperforming SPY on both 5d and 30d bases, and the 10Y yield at 5.24% is a structural headwind for a dividend-paying biotech. No insider buying, no unusual call flow, and no analyst upgrade signals are present to provide confirmation of a rebound.
?Oct 5, 12:20 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
AMGN is a financially established large-cap biotech with no evidence of fundamental deterioration in recent filings. However, the options flow is a significant red flag — the P/C ratio of 2.81 with call volume deeply below normal (z=-3.85) and put volume elevated (z=0.91) is an unusual bearish signal on a dipping stock, suggesting informed traders are positioning defensively. Additionally, earnings are 28 days away, which is a meaningful headwind (-1), the 10Y yield at 5.24% is a structural headwind for duration-sensitive biotech (-1), and the Health Care sector is underperforming SPY (-4.53pts over 30 days, +1), though not in freefall. The drop of only 10.5% does not meet the 15% threshold for a mean-reversion bonus, and there are no insider buys to support the thesis.
!Oct 5, 12:20 PMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
AMGN is a financially established large-cap biotech with no evidence of fundamental deterioration in recent filings. However, the options flow is a significant red flag — the P/C ratio of 2.81 with call volume deeply below normal (z=-3.85) and put volume elevated (z=0.91) is an unusual bearish signal on a dipping stock, suggesting informed traders are positioning defensively. Additionally, earnings are 28 days away, which is a meaningful headwind (-1), the 10Y yield at 5.24% is a structural headwind for duration-sensitive biotech (-1), and the Health Care sector is underperforming SPY (-4.53pts over 30 days, +1), though not in freefall. The drop of only 10.5% does not meet the 15% threshold for a mean-reversion bonus, and there are no insider buys to support the thesis.
?Oct 5, 11:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip
AMGN is a financially established large-cap biotech with no evidence of fundamental deterioration in recent filings. However, the options flow is a significant red flag — the P/C ratio of 2.81 with call volume deeply below normal (z=-3.85) and put volume elevated (z=0.91) is an unusual bearish signal on a dipping stock, suggesting informed traders are positioning defensively. Additionally, earnings are 28 days away, which is a meaningful headwind (-1), the 10Y yield at 5.24% is a structural headwind for duration-sensitive biotech (-1), and the Health Care sector is underperforming SPY (-4.53pts over 30 days, +1), though not in freefall. The drop of only 10.5% does not meet the 15% threshold for a mean-reversion bonus, and there are no insider buys to support the thesis.
!Oct 5, 11:21 AMsignalseverity 0.11
Agent 5 — Dip Buyer (Evolving) — dip_skipped
AMGN is a financially established large-cap biotech with no evidence of fundamental deterioration in recent filings. However, the options flow is a significant red flag — the P/C ratio of 2.81 with call volume deeply below normal (z=-3.85) and put volume elevated (z=0.91) is an unusual bearish signal on a dipping stock, suggesting informed traders are positioning defensively. Additionally, earnings are 28 days away, which is a meaningful headwind (-1), the 10Y yield at 5.24% is a structural headwind for duration-sensitive biotech (-1), and the Health Care sector is underperforming SPY (-4.53pts over 30 days, +1), though not in freefall. The drop of only 10.5% does not meet the 15% threshold for a mean-reversion bonus, and there are no insider buys to support the thesis.
?Oct 5, 11:21 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
AMGN is a fundamentally sound large-cap biotech with no confirmed negative catalyst driving the 10.5% drop from the 30-day high. However, the options flow is a significant concern — highly unusual put volume (P/C ratio of 2.81, call z-score of -3.85) on the most recent trading day suggests informed hedging or directional bearish positioning, not a bullish overreaction setup. Earnings are 28 days away (elevated caution zone), sector health care is underperforming SPY on both 5d and 30d bases, and the 10Y yield at 5.24% is a structural headwind for a dividend-paying biotech. No insider buying, no unusual call flow, and no analyst upgrade signals are present to provide confirmation of a rebound.
!Oct 5, 11:21 AMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is a fundamentally sound large-cap biotech with no confirmed negative catalyst driving the 10.5% drop from the 30-day high. However, the options flow is a significant concern — highly unusual put volume (P/C ratio of 2.81, call z-score of -3.85) on the most recent trading day suggests informed hedging or directional bearish positioning, not a bullish overreaction setup. Earnings are 28 days away (elevated caution zone), sector health care is underperforming SPY on both 5d and 30d bases, and the 10Y yield at 5.24% is a structural headwind for a dividend-paying biotech. No insider buying, no unusual call flow, and no analyst upgrade signals are present to provide confirmation of a rebound.
!Oct 5, 10:20 AMsignalseverity 0.10
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is a fundamentally sound large-cap biotech with no confirmed negative catalyst driving the 10.5% drop from the 30-day high. However, the options flow is a significant concern — highly unusual put volume (P/C ratio of 2.81, call z-score of -3.85) on the most recent trading day suggests informed hedging or directional bearish positioning, not a bullish overreaction setup. Earnings are 28 days away (elevated caution zone), sector health care is underperforming SPY on both 5d and 30d bases, and the 10Y yield at 5.24% is a structural headwind for a dividend-paying biotech. No insider buying, no unusual call flow, and no analyst upgrade signals are present to provide confirmation of a rebound.
!Oct 5, 10:20 AMsignalseverity 0.10
Agent 5 — Dip Buyer (Evolving) — dip_skipped
AMGN is a financially established large-cap biotech with no evidence of fundamental deterioration in recent filings. However, the options flow is a significant red flag — the P/C ratio of 2.81 with call volume deeply below normal (z=-3.85) and put volume elevated (z=0.91) is an unusual bearish signal on a dipping stock, suggesting informed traders are positioning defensively. Additionally, earnings are 28 days away, which is a meaningful headwind (-1), the 10Y yield at 5.24% is a structural headwind for duration-sensitive biotech (-1), and the Health Care sector is underperforming SPY (-4.53pts over 30 days, +1), though not in freefall. The drop of only 10.5% does not meet the 15% threshold for a mean-reversion bonus, and there are no insider buys to support the thesis.
!Oct 1, 12:45 PMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
AMGN is down 2.59% today, a meaningful move suggesting real selling pressure. The headline about Lilly vs. Novo at EASD is GLP-1/diabetes-focused and not directly about AMGN, but continued investor attention on competing biopharma names can weigh on broader biotech sentiment including AMGN. The macro context shows 5-year forward inflation expectations elevated at 2.0σ above trend, which is modestly negative for rate-sensitive equities including large-cap biotech with high valuation multiples. With 180 minutes remaining there is ample time for the move to extend, and a 2.59% drop of this size typically reflects institutional-scale selling that does not fully resolve intraday. However, there is no direct AMGN-specific catalyst identified, the move may have already captured much of the session's flow, and elevated inflation expectations could cut both ways for pharma names. No clear reversal pattern is evident, so the base case is modest continuation rather than a strong fade. Probability set at 0.52 — slight lean toward continuation given time remaining and size of move, but conviction is low without a clean fundamental driver.
!Sep 25, 3:21 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
AMGN is up 2.05% today, which represents meaningful intraday conviction. However, with only 25 minutes remaining until the forced close at 3:45 PM ET, the time window is extremely constrained — even a legitimate continuation setup has limited runway to reach the +3% profit target from current levels (would require another ~1% move). The macro context is mildly unfavorable: T5YIFR running 1.6σ above trend signals elevated forward inflation expectations, which pressures rate-sensitive and high-multiple biotech/pharma names like AMGN. No AMGN-specific headlines are present to anchor or explain the move, and the available headlines are entirely unrelated to the ticker. The absence of a catalyst doesn't disqualify the trade, but combined with the late-session timing and a slightly hawkish macro read, the risk/reward tilts unfavorable. Late-session fades on unexplained biotech moves after a 2%+ run are common. Probability falls below the 0.5 threshold, so no position is warranted.
!Sep 22, 10:21 AMsignalseverity 0.11
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
!Sep 22, 7:00 AMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
▢Sep 21, 8:00 PMjournal
Agent 7 — Day Trader opened long 7 @ $399.49
▣Sep 21, 8:00 PMjournaltarget
Agent 7 — Day Trader closed long 7 @ $412.27 (+$89.42)
Long target: close $412.26 ≥ target $411.47
!Sep 21, 4:21 PMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
!Sep 21, 3:20 PMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
!Sep 21, 2:20 PMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
!Sep 21, 1:20 PMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
!Sep 21, 12:21 PMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
!Sep 21, 12:20 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
AMGN is up 1.66% today, a meaningful but not outsized intraday move. No single catalyst headline is driving this — the Zacks blog mention is noise, not a catalyst. The macro context shows DFEDTARU at 4.0%, elevated relative to trend, which is a mild headwind for biotech/pharma (higher discount rates compress long-duration growth names), though AMGN is more of a value/dividend play in the sector and less rate-sensitive than pure-growth biotech. With 205 minutes remaining there is ample time for continuation, but also ample time for a fade if no fresh catalyst emerges. The move is below the 2% threshold where strong conviction flow is typically presumed. Volume context is unknown, which prevents a higher conviction read. Overall, the base case is modest continuation given the time remaining and lack of a clear reversal signal, but the absence of a strong catalyst and the mild macro headwind from elevated rates temper enthusiasm. Assigning a slight edge to continuation above the 0.5 threshold given the directional momentum and time remaining, but not enough evidence for a high-conviction setup.
!Sep 21, 11:21 AMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
!Sep 21, 10:20 AMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
!Sep 21, 7:00 AMsignalseverity 0.14
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
AMGN is down 11.4% from its 30-day high with no identifiable news catalyst, SEC filings with no disclosed metrics, and no insider activity — making the drop ambiguous and likely macro/sector-driven rather than fundamentally impaired. Options flow is supportive with a low P/C ratio (0.38) and put volume at a notably negative z-score (-1.87), suggesting limited directional bearishness; call activity is roughly neutral. Healthcare sector is outperforming SPY on both 5d and 30d bases, which means AMGN is dipping while its sector holds up — implying some idiosyncratic pressure, but without a confirmed negative catalyst. Earnings are 55 days away (non-factor), and VIX is very low (14.32, 2nd percentile), suggesting a calm macro backdrop. However, the 10Y yield at 4.77% and elevated 5Y forward inflation rate (1.7σ above trend) are modest headwinds for a large-cap biotech. Without a clear recovery catalyst or cluster insider buying, the setup lacks the asymmetric large-rebound profile this strategy targets.
▢Sep 10, 8:00 PMjournal
Agent 4 — Dip Buyer (Frozen) opened long 2 @ $377.35

← Back to dashboard